ARTVIGIL 250

What is ARTVIGIL 250?

ARTVIGIL 250 is a modern pharmaceutical drug from the group of nootropics and central nervous system stimulants, the active ingredient of which is armodafinil. The drug is produced in the form of tablets for oral administration with a fixed dosage of 250 mg, which provides a predictable pharmacological response of the body over a long period. The manufacturer of ARTVIGIL 250 is HAB Pharmaceuticals, a company that has established itself as a reliable producer of high-quality pharmaceutical products with controlled bioavailability. The drug belongs to the category of agents that help maintain wakefulness and cognitive activity, and is used to correct conditions associated with excessive daytime sleepiness. Armodafinil is the R-enantiomer of modafinil, which results in a longer elimination half-life and a more stable concentration of the active substance in blood plasma compared to the racemic mixture.

ARTVIGIL 250 stands out among other stimulants due to its special mechanism of action, which does not involve the massive release of dopamine characteristic of classic amphetamine-type psychostimulants. Thanks to this, the drug has a significantly lower potential for developing dependence and less pronounced cardiovascular side effects. The pharmacological action of ARTVIGIL 250 is realized through its effect on the hypothalamic centers regulating sleep-wake cycles, as well as through the modulation of neurotransmitter system activity. Clinical studies demonstrate that armodafinil effectively increases the level of alertness without significantly disrupting nighttime sleep architecture with a proper dosage regimen. The drug is especially valued by patients who require long-term concentration and mental performance under conditions of sleep deprivation or a shift work schedule.

The therapeutic profile of ARTVIGIL 250 covers not only the elimination of sleepiness, but also the improvement of executive brain functions, working memory, and information processing speed. The drug is available in blisters, which provides protection from moisture and light, preserving the stability of the active component throughout its shelf life. HAB Pharmaceuticals applies modern quality control standards at all stages of production, guaranteeing that each tablet corresponds to the declared dosage. ARTVIGIL 250 is a prescription drug in most countries, so its use should take place exclusively under the supervision of a qualified physician. Self-medication with this agent is unacceptable, as an improper dosage regimen can provoke undesirable reactions from the nervous system.

What is ARTVIGIL 250 prescribed for?

The main indication for prescribing ARTVIGIL 250 is narcolepsy — a chronic neurological disorder characterized by irresistible attacks of daytime sleep and sudden loss of muscle tone. The drug helps patients with this diagnosis maintain a stable level of wakefulness throughout the day, which significantly improves quality of life and social adaptation. Clinical observations show that regular intake of armodafinil reduces the frequency of sudden falling asleep episodes by 60–80 percent in most patients. It is important to understand that ARTVIGIL 250 does not cure narcolepsy, but it effectively controls its symptoms, allowing a person to lead a full lifestyle. Therapy is usually long-term and requires regular medical monitoring to evaluate effectiveness and adjust the dose.

The second important indication is obstructive sleep apnea syndrome, in which patients suffer from severe daytime sleepiness due to repeated breathing pauses during nighttime sleep. ARTVIGIL 250 is prescribed as an adjunct to primary therapy, which is usually CPAP therapy or other methods of correcting breathing disorders. The drug helps overcome residual sleepiness in cases where mechanical ventilation does not completely eliminate symptoms. Combining the main treatment with armodafinil allows patients to resume professional activities and avoid dangerous situations associated with falling asleep at the wheel. The doctor evaluates the appropriateness of such a combined approach individually for each patient.

ARTVIGIL 250 is also used for shift work sleep disorders, when professional activity requires activity at night or involves frequent changes of time zones. The drug helps adapt the body's circadian rhythms to non-standard conditions, reducing the feeling of exhaustion and improving concentration during periods when the body is naturally inclined to sleep. In some clinical situations, a doctor may prescribe ARTVIGIL 250 off-label to correct severe asthenia associated with chronic diseases or a recovery period after severe infections. However, such use requires special caution and careful weighing of potential benefits and risks. The decision to prescribe the drug is always made by a physician based on a comprehensive clinical examination.

Composition and active components of ARTVIGIL 250

The active pharmaceutical ingredient of ARTVIGIL 250 is armodafinil at a dosage of 250 mg per tablet. Armodafinil is a chemically pure R-enantiomer of modafinil, which has a higher affinity for dopamine transporters in the brain and a longer elimination half-life of approximately 15 hours. This pharmacokinetic feature allows the drug to be taken once daily while maintaining a therapeutic effect throughout the entire wakeful period. The mechanism of action of armodafinil consists of the selective inhibition of dopamine reuptake, which leads to an increase in its concentration in the synaptic cleft and the activation of dopaminergic pathways responsible for maintaining wakefulness. Unlike amphetamines, armodafinil does not cause a sharp release of monoamines, so its stimulating effect is more physiological and less toxic to neurons.

The excipients of ARTVIGIL 250 include microcrystalline cellulose, which acts as a filler and ensures the structural integrity of the tablet, croscarmellose sodium as a disintegrant for rapid dissolution of the tablet in the gastrointestinal tract, and povidone as a binding agent. The composition also includes magnesium stearate, which prevents the tablet mass from sticking to equipment during compression, and lactose monohydrate, which gives the tablet the necessary mass and improves its organoleptic properties. All excipients are of pharmacopoeial quality and have no independent pharmacological action at the concentrations used. The manufacturer HAB Pharmaceuticals strictly controls the purity and ratio of all components, guaranteeing the stability of the drug throughout the declared shelf life.

The pharmacodynamics of armodafinil also includes an effect on the orexin system of the hypothalamus, which plays a key role in regulating the transition between sleep and wakefulness. Additionally, the drug modulates the activity of histaminergic neurons and inhibits GABAergic transmission in certain areas of the brain, which overall provides a pronounced wake-promoting effect without feelings of anxiety or excessive agitation. The metabolism of armodafinil occurs primarily in the liver with the participation of cytochrome P450 system enzymes, particularly the CYP3A4 isoenzyme, forming inactive metabolites that are excreted by the kidneys. Understanding these biochemical processes is important for assessing potential drug interactions and individualizing dose selection for patients with impaired liver or kidney function.

Dosage of ARTVIGIL 250

The standard recommended dose of ARTVIGIL 250 for adult patients is 250 mg once daily, usually in the morning or one hour before starting a work shift. This dosage regimen provides a stable concentration of armodafinil in the blood throughout the period of active activity and minimizes the risk of disrupting night sleep. For patients with narcolepsy or obstructive sleep apnea syndrome, taking the drug is recommended at the same time every morning, which contributes to establishing a sustained therapeutic effect. In cases where the clinical response is insufficient, the doctor may consider increasing the dose to 250 mg twice daily; however, such a decision is made only after a careful assessment of drug tolerability. The maximum daily dose should not exceed 500 mg, as further increases are not accompanied by a proportional enhancement of effect, but increase the likelihood of adverse reactions.

For elderly patients over 65 years of age, a dose adjustment may be required due to an age-related decrease in metabolic rate and the possible presence of concomitant liver or kidney diseases. In such cases, therapy usually begins with the minimum effective dose, which may be half of a 250 mg tablet, followed by titration under medical supervision. For patients with severe hepatic impairment, a 50 percent dose reduction is recommended due to the slowing of armodafinil biotransformation in the liver. For mild to moderate renal impairment, dose adjustment is usually not required; however, with a creatinine clearance below 20 ml/min, the drug should be used with extreme caution. The duration of the treatment course is determined individually depending on the diagnosis, severity of symptoms, and response to therapy.

It is important to note that ARTVIGIL 250 is not intended for use in pediatric practice, as the safety and efficacy of the drug in persons under 18 years of age have not been established. Discontinuation of therapy usually does not require a gradual dose reduction, as armodafinil has a low potential for withdrawal syndrome compared to classic psychostimulants. However, in patients who have taken the drug for a long time at high doses, a temporary feeling of fatigue and sleepiness is possible after abrupt discontinuation, so a doctor may recommend a gradual dose reduction over one to two weeks. Regular medical monitoring during therapy includes control of blood pressure, heart rate, and evaluation of the patient's mental state.

How to take ARTVIGIL 250 correctly?

ARTVIGIL 250 should be taken orally with a sufficient amount of water, regardless of food intake, although taking the drug with food may slightly delay the rate of its absorption. To achieve the maximum therapeutic effect, the tablet is recommended to be taken in the morning immediately after waking up or one hour before the start of a work shift for individuals with a shift schedule. Taking the drug in the second half of the day can lead to significant difficulty falling asleep and disruption of the natural structure of night sleep, so patients should strictly adhere to the recommended time of intake. The tablet should not be chewed or crushed, as this may disrupt the pharmacokinetic profile of the drug and lead to an uneven release of the active substance. If a patient forgets to take a regular dose, it should be taken as soon as possible; however, if less than 8 hours remain until the next dose, the missed dose should be skipped to avoid drug accumulation and sleep disturbance.

During ARTVIGIL 250 therapy, patients are advised to maintain a regular sleep schedule and avoid chronic sleep deprivation, as the drug does not replace the body's physiological need for rest. Despite its stimulating effect, armodafinil does not restore cognitive functions impaired as a result of prolonged sleep deprivation, but only masks the feeling of fatigue for a limited period. Patients taking the drug should refrain from driving vehicles and operating dangerous machinery until their individual reaction to treatment has been established. Although armodafinil rarely causes dizziness or impaired coordination, transient changes in psychomotor reactions may occur in some sensitive individuals at the start of therapy. Alcohol consumption during treatment is strictly not recommended, as ethanol can enhance side effects on the central nervous system and negate the therapeutic effect of the drug.

Particular attention should be paid to body hydration, as armodafinil can cause dry mouth and a reduced sense of thirst, which, with insufficient fluid intake, leads to dehydration. Patients with cardiovascular diseases need to regularly monitor blood pressure and heart rate, especially in the first weeks of therapy. Women of reproductive age taking ARTVIGIL 250 should use reliable methods of contraception, as armodafinil can reduce the effectiveness of hormonal contraceptives due to the induction of liver enzymes. Before starting therapy, a doctor must conduct a complete examination, including an electrocardiogram, assessment of liver and kidney function, and rule out the presence of psychiatric disorders that could exacerbate under the influence of a stimulant.

Side effects of ARTVIGIL 250

The most common side effects of ARTVIGIL 250 are headaches, which occur in approximately 20 percent of patients at the beginning of therapy and usually diminish during the first week of treatment. Nausea, dry mouth, decreased appetite, and feelings of anxiety are also frequently observed; these are transient in nature and do not require discontinuation of the drug in most cases. Insomnia is an expected side effect when the dosage regimen is violated, particularly when taking the drug in the second half of the day, so patients should strictly adhere to the recommendations regarding administration time. Some patients may experience an increase in blood pressure and heart rate, which requires regular monitoring of hemodynamic indicators, especially in individuals with pre-existing arterial hypertension. Most side effects are dose-dependent and disappear after dose adjustment or adaptation of the body to the drug.

Less common side effects include skin reactions, including rash, itching, and urticaria, which may indicate the development of hypersensitivity to the drug's components. Serious dermatological reactions, such as Stevens-Johnson syndrome or toxic epidermal necrolysis, occur extremely rarely, but require immediate drug discontinuation and urgent medical attention. On the part of the mental sphere, irritability, emotional lability, depressive episodes, or, conversely, euphoria are possible, requiring careful observation of the patient's mental state throughout the treatment period. In isolated cases, the development of psychotic symptoms, hallucinations, and manic states has been reported, especially in patients with a history of psychiatric conditions. The appearance of any unusual symptoms is a reason to consult a doctor and review the treatment strategy.

Patients should seek medical help immediately if they experience chest pain, heart rhythm disturbances, severe shortness of breath, or syncopal states, as these symptoms may indicate serious cardiovascular complications. The body's individual response to ARTVIGIL 250 can vary significantly depending on genetic metabolic characteristics, age, sex, and the presence of concomitant diseases. Therefore, it is important to inform your doctor about all changes in well-being during therapy, even if they seem insignificant. In case of allergic reactions, angioedema, or difficulty breathing, the drug should be immediately discontinued and emergency medical assistance sought. Regular medical supervision allows for the timely detection of adverse events and adjustment of therapy to achieve an optimal balance between efficacy and safety.

Contraindications of ARTVIGIL 250

ARTVIGIL 250 has clear contraindications that must be considered before starting therapy. An absolute contraindication is hypersensitivity to armodafinil, modafinil, or any excipient component of the drug, which may manifest as allergic reactions of varying severity. The drug is prohibited for use in patients with severe arterial hypertension, uncontrolled heart rhythm disorders, and other serious cardiovascular diseases, as the stimulating effect can provoke decompensation of the condition. The presence of left ventricular hypertrophy, mitral valve prolapse, or ischemic heart disease in a patient requires special caution and a thorough cardiological examination before prescribing the drug. For patients with psychotic disorders, bipolar affective disorder, or severe depression, ARTVIGIL 250 is contraindicated due to the risk of exacerbating psychiatric symptoms.

Pregnancy and lactation are contraindications to the use of ARTVIGIL 250, as data on the safety of armodafinil for the fetus and infant are lacking. Animal studies have shown potential adverse effects on embryonic development; therefore, women of reproductive age are recommended to use effective methods of contraception during therapy and for one month after its completion. The drug is not prescribed to children and adolescents under 18 years of age due to the lack of sufficient clinical data on safety and efficacy in this age group. For patients with severe hepatic impairment, liver cirrhosis, or active liver disease, the drug is contraindicated or prescribed with a significant dose adjustment under strict laboratory control. A history of drug addiction, alcoholism, or substance abuse is also a relative contraindication requiring an individual assessment of the benefit-risk ratio.

For patients with epilepsy or seizure disorders, ARTVIGIL 250 should be prescribed with extreme caution, as the stimulating effect on the central nervous system can lower the seizure threshold. Individuals with severe renal impairment require an individual approach to dosage and regular monitoring of creatinine clearance. Before starting therapy, the doctor is obliged to conduct a complete medical examination, including taking a medical history, physical examination, electrocardiography, and laboratory tests of liver and kidney function. Only after a thorough evaluation of all risk factors can a decision be made regarding the appropriateness of using ARTVIGIL 250 in a specific patient. Self-medication with this drug is strictly prohibited and can lead to serious health consequences.

Interaction of ARTVIGIL 250 with other drugs and alcohol

ARTVIGIL 250 enters into clinically significant interactions with many drugs through its effect on the cytochrome P450 enzyme system, specifically on the CYP3A4 isoenzyme. The drug can reduce the effectiveness of hormonal contraceptives, so women taking oral contraceptives are advised to use additional barrier methods of protection during therapy and for one month after its completion. Concomitant use with anticoagulants, such as warfarin, requires regular monitoring of blood clotting parameters, as armodafinil can alter the metabolism of these drugs. Patients taking antidepressants, especially tricyclics or monoamine oxidase inhibitors, should inform their doctor, as the combination with armodafinil can enhance stimulating effects and increase the risk of developing serotonin syndrome. Interaction with antiepileptic drugs can lead to a decrease in their blood concentration and an increased risk of seizures.

Alcohol consumption during ARTVIGIL 250 therapy is strictly not recommended, as ethanol can unpredictably alter the body's pharmacological response to the drug. Combining a stimulant with alcohol creates an excessive burden on the cardiovascular system, increases the risk of developing arrhythmias and hypertensive crises, and can also mask the symptoms of alcohol intoxication, leading to dangerous situations. Patients taking ARTVIGIL 250 should be cautious when driving vehicles and operating machinery, especially at the beginning of therapy or when changing doses, as the individual reaction to the drug may include dizziness or impaired concentration. The drug can enhance the action of other central nervous system stimulants, including caffeine, so patients are recommended to limit consumption of coffee and energy drinks during treatment. Any changes in the therapy regimen or the addition of new medications must be coordinated with a doctor to avoid potentially dangerous interactions.

Where to buy ARTVIGIL 250 in Ukraine

ARTVIGIL 250 is available for purchase in licensed pharmacies in Ukraine with a prescription issued by a qualified doctor. The drug can also be ordered through verified online platforms specializing in the delivery of pharmaceutical products; however, it is important to ensure the availability of appropriate licenses and quality certificates. When purchasing, attention should be paid to the integrity of the packaging, expiration date, and the presence of protective elements confirming the authenticity of the product from the manufacturer HAB Pharmaceuticals. ARTVIGIL 250 must be stored in a dry place protected from light at a temperature not exceeding 25 degrees Celsius, out of the reach of children. Failure to observe storage conditions may lead to a decrease in the therapeutic efficacy of the drug and the formation of undesirable degradation products of the active substance.

Before purchasing and using ARTVIGIL 250, be sure to consult a doctor, who will evaluate the appropriateness of therapy, rule out contraindications, and select an individual dosage regimen. Remember that the body's individual response to the drug may vary, so self-medication is unacceptable and can harm your health. The information provided in this description is for informational purposes only and does not replace professional medical advice. Only a qualified specialist can determine the need for using ARTVIGIL 250, taking into account all the features of a specific patient's health status and potential risks of drug interactions.